ReviewToxicology and applied pharmacology2007
Silymarin and epithelial cancer chemoprevention: how close we are to bedside?
Review in Toxicology and applied pharmacology, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Silymarin for adults with metabolic dysfunction-associated steatotic liver disease.The Cochrane database of systematic reviews · 2025Pooled it
- Article
- Mechanistic Insights into Silymarin-Induced Apoptosis and Growth Inhibition in SPC212 Human Mesothelioma Cells.Cell biochemistry and biophysics · 2025Article
- Biocontrol Agents and Natural Feed Supplements as a Safe and Cost-Effective Way for Preventing Health Ailments Provoked by Mycotoxins.Foods (Basel, Switzerland) · 2025Review
- Prooxidant state in anticancer drugs and prospect use of mitochondrial cofactors and anti-inflammatory agents in cancer prevention.Inflammopharmacology · 2025Review
- Milk Thistle (Current medicinal chemistry · 2025Review
- Inhibition of cytotoxic fibril formation of α-synuclein and human insulin by Silymarin from the Silybum marianum.PloS one · 2025Article
- The importance of integrated therapies on cancer: Silibinin, an old and new molecule.Oncotarget · 2024Review
- Natural feed additives and bioactive supplements versus chemical additives as a safe and practical approach to combat foodborne mycotoxicoses.Frontiers in nutrition · 2024Review
- Pharmaceutical prospects of Silymarin for the treatment of neurological patients: an updated insight.Frontiers in neuroscience · 2023Review
- Mechanistic Insights into the Pharmacological Significance of Silymarin.Molecules (Basel, Switzerland) · 2022Review
- The Possible Neuroprotective Effect of Silymarin against Aluminum Chloride-Prompted Alzheimer's-Like Disease in Rats.Brain sciences · 2020Article
- Development of an HPLC-MS/MS Method for the Determination of Silybin in Human Plasma, Urine and Breast Tissue.Molecules (Basel, Switzerland) · 2020Article
- Multidrug Resistance Modulation Activity of Silybin Derivatives and Their Anti-inflammatory Potential.Antioxidants (Basel, Switzerland) · 2020Article
- Therapeutic Efficacy of Palmitoylethanolamide and Its New Formulations in Synergy with Different Antioxidant Molecules Present in Diets.Nutrients · 2019Review
- Silibinin efficacy in a rat model of pulmonary arterial hypertension using monocrotaline and chronic hypoxia.Respiratory research · 2019Article
- Review
- Concurrent administration of anticancer chemotherapy drug and herbal medicine on the perspective of pharmacokinetics.Journal of food and drug analysis · 2018Review
- Protective Effects of Silymarin and Silibinin against DNA Damage in Human Blood Cells.BioMed research international · 2018Article
- Evaluation of the Cytotoxicity and Genotoxicity of Flavonolignans in Different Cellular Models.Nutrients · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
Failure and high systemic toxicity of conventional cancer therapies have accelerated the focus on the search for newer agents, which could prevent and/or slow-down cancer growth and have more human acceptability by being less or non-toxic. Silymarin is one such agent, which has been extensively used since ages for the treatment of liver conditions, and thus has possibly the greatest patient acceptability. In recent years, increasing body of evidence has underscored the cancer preventive efficacy of silymarin in both in vitro and in vivo animal models of various epithelial cancers. Apart from chemopreventive effects, other noteworthy aspects of silymarin and its active constituent silibinin in cancer treatment include their capability to potentiate the efficacy of known chemotherapeutic drugs, as an inhibitor of multidrug resistance-associated proteins and as an adjunct to the cancer therapeutic drugs due to their organ-protective efficacy specifically liver, and immunostimulatory effects. Widespread use of silymarin for liver health in humans and commercial availability of its formulations with increased bioavailability, further underscore the necessity of carrying out controlled clinical trials with these agents in cancer patients. In this review, we will briefly discuss the outcomes of clinical trials being conducted by us and others in cancer patients to provide insight into the clinical relevance of the observed chemopreventive effects of these agents in various epithelial cancer models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.